Alector, Inc.

Healthcare · Biotechnology · United States

Last price 2.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 327.65M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body...